Synta 'Window' Opens Wider: Breast Cancer Phase II Positive
By Randy Osborne
Monday, July 29, 2013
While they are waiting for data from the non-small-cell lung cancer (NSCLC) program with Synta Pharmaceutical Corp.'s heat-shock protein 90 (Hsp90) inhibitor ganetespib, investors got a nice surprise from the Phase II effort in locally advanced or metastatic HER2-positive or triple-negative breast cancer (TNBC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.